Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strategy

Set Alert for Strategy

Can Sanofi’s Toujeo Prickle Tresiba In India?

Sanofi has launched its next generation basal insulin, Toujeo, on the Indian market at a significantly reduced per unit price point versus Novo Nordisk’s Tresiba (insulin degludec), setting the stage for an interesting market expansion battle.

India Pricing Strategies Metabolic Disorders
Advertisement

Strategy

Set Alert for Strategy

Latest From Strategy

Jobs Go At Shield Therapeutics As Failed Study Fallout Hits

Shield Therapeutics is to slash its workforce and is considering a possible sale in the wake of a failed Phase III study for its only marketed product, Ferracru, that should have given it access to the US market.

Companies Commercial

Preparing Emerging Biotechs For The Best Deals – Insider Insights

As the market for pharma and biotech deal making heats up in 2018, Scrip looks at the process of valuing novel companies with emerging data and collects best advice from experts on how start-ups should pitch to potential pharma partners.

Business Strategies Deals

Waking Up Market To US Obstructive Sleep Apnea Epidemic

RespireRx president & CEO James Manuso explained to Scrip during the 2018 Biotech Showcase how the company is repurposing an existing drug to tackle the problem of sleep apnea.

Clinical Trials Companies

Nektar/Bristol Deal May Shake Up Immuno-Oncology Landscape

The multibillion-dollar collaboration includes 20 studies, including two pivotal trials in renal cell carcinoma and non-small cell lung cancer that will start in the middle of the year.

Deals ImmunoOncology

A First For Prostate Cancer: Janssen's Erleada Approved For Non-Metastatic Patients

J&J subsidiary Janssen's Erleada (apalutamide) is the first therapy approved for non-metastatic castration-resistant prostate cancer (nmCRPC). The US FDA decision came about two months early, but the drug – priced at $10,920 per month, or $131,040 annually – may soon face competition.
Approvals Cancer
See All
UsernamePublicRestriction

Register